Metabolic Dysfunction-Associated Fatty Liver Disease: From Pathogenesis to Treatment

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most prevalent chronic liver disease worldwide and represents a major hepatic manifestation of systemic metabolic dysfunction. The disease is closely linked to obesity and insulin resistance and progresses from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Increasing evidence indicates that MAFLD pathogenesis involves complex interactions among dysregulated lipid metabolism, mitochondrial dysfunction, oxidative stress, inflammatory signaling, bile acid imbalance, and gut microbiota-derived metabolites, reflecting the systemic and multifactorial nature of the disease. However, despite substantial progress in understanding these mechanisms, the integrated regulatory networks driving MAFLD progression and their translational therapeutic implications remain incompletely characterized. In this review, we comprehensively summarize recent advances in the molecular mechanisms underlying MAFLD, focusing on metabolic dysregulation, cellular stress responses, inflammatory pathways, and regulated cell death processes. We further highlight the critical role of interorgan communication particularly the adipose–liver and gut–liver axes and discuss emerging evidence on extracellular vesicles (EVs) as mediators of metabolic and inflammatory signaling. Finally, we evaluate current and potential therapeutic strategies, emphasizing the diagnostic and therapeutic promise of EV-based approaches in MAFLD management, and identifying emerging molecular targets for improved intervention and future clinical translation opportunities.

Keywords

adipose–liver crosstalk / engineered EVs / EVs / gut–liver axis / MAFLD

References

[1] L. Tao, X. Yang, C. Ge, et al., “Integrative Clinical and Preclinical Studies Identify FerroTerminator1 as a Potent Therapeutic Drug for MASH,” Cell Metabolism 36, no. 10 (2024): 2190–2206.e2195.

[2] M. Eslam, A. J. Sanyal, and J. George, “MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease,” Gastroenterology 158, no. 7 (2020): 1999–2014.e1991.

[3] T. Y. Wang, R. F. Wang, Z. Y. Bu, et al., “Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Kidney Disease,” Nature Reviews Nephrology 18, no. 4 (2022): 259–268.

[4] M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Hepatology 78, no. 6 (2023): 1966–1986.

[5] A. Yang, X. Zhu, L. Zhang, et al., “Transitioning From NAFLD to MAFLD and MASLD: Consistent Prevalence and Risk Factors in a Chinese Cohort,” Journal of Hepatology 80, no. 4 (2024): e154–e155.

[6] M. Eslam, P. N. Newsome, S. K. Sarin, et al., “A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement,” Journal of Hepatology 73, no. 1 (2020): 202–209.

[7] N. Méndez-Sánchez, E. Bugianesi, R. G. Gish, et al., “Global Multi-Stakeholder Endorsement of the MAFLD Definition,” Lancet Gastroenterology & Hepatology 7, no. 5 (2022): 388–390.

[8] Z. M. Younossi, S. Zelber-Sagi, J. V. Lazarus, et al., “Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis,” Gastroenterology 169, no. 5 (2025): 1017–1032.e1012.

[9] J. P. Arab, L. A. Díaz, J. Rehm, et al., “Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD): Position Statement by an Expert Panel on Alcohol-Related Liver Disease,” Journal of Hepatology 82, no. 4 (2025): 744–756.

[10] N. Torp, K. T. Bech, H. L. Schnefeld, et al., “Phosphatidylethanol and Self-Reported Alcohol Intake to Subclassify Individuals at Risk of Steatotic Liver Disease: An Analysis of Data From a Prospective Cohort Study,” Lancet Gastroenterology & Hepatology 10, no. 11 (2025): 975–985.

[11] P. Ginès, M. Serra-Burriel, and P. S. Kamath, “Metabolic Dysfunction-Associated Steatotic Liver Disease-The New Epidemic of Chronic Liver Disease,” JAMA Network Open 8, no. 6 (2025): e2516381.

[12] J. Zeng, C. Gu, C. Wen, et al., “The Burden of NAFLD (Now Referred to as MASLD)-Related Chronic Liver Disease and Cirrhosis From 1990 to 2021 With Projections to 2036: A Comparative Study of Global China the United States and India,” Lipids in Health And Disease 24, no. 1 (2025): 298.

[13] G. J. K. Ho, F. X. N. Tan, N. A. Sasikumar, et al., “High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-Analysis,” Clinical Gastroenterology And Hepatology 23, no. 13 (2025): 2423–2432.e2421.

[14] P. Danpanichkul, K. Suparan, V. Prasitsumrit, et al., “Long-Term Outcomes and Risk Modifiers of Metabolic Dysfunction-Associated Steatotic Liver Disease Between Lean and Non-Lean Populations,” Clinical And Molecular Hepatology 31, no. 1 (2025): 74–89.

[15] P. Le, M. Tatar, S. Dasarathy, et al., “Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050,” JAMA Network Open 8, no. 1 (2025): e2454707.

[16] E. E. Powell, V. W. Wong, and M. Rinella, “Non-Alcoholic Fatty Liver Disease,” Lancet 397, no. 10290 (2021): 2212–2224.

[17] J. Z. Shu, Y. H. Huang, X. H. He, et al., “Gut Microbiota Differences, Metabolite Changes, and Disease Intervention During Metabolic—dysfunction—related Fatty Liver Progression,” World Journal of Hepatology 17, no. 3 (2025): 103854.

[18] M. C. C. Cheah, H. Crane, and J. George, “Global Prevalence, Metabolic Characteristics, and Outcomes of Lean-MAFLD: A Systematic Review and Meta-Analysis,” Hepatology International 19, no. 3 (2025): 607–618.

[19] Z. Hu, H. Yue, N. Jiang, et al., “Diet, Oxidative Stress and MAFLD: A Mini Review,” Frontiers in Nutrition 12 (2025): 1539578.

[20] H. Tilg, T. E. Adolph, and A. R. Moschen, “Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade,” Hepatology 73, no. 2 (2021): 833–842.

[21] M. Habibullah, K. Jemmieh, A. Ouda, et al., “Metabolic-Associated Fatty Liver Disease: A Selective Review of Pathogenesis, Diagnostic Approaches, and Therapeutic Strategies,” Frontiers in Medicine 11 (2024): 1291501.

[22] G. Xourafa, M. Korbmacher, and M. Roden, “Inter-Organ Crosstalk During Development and Progression of Type 2 Diabetes Mellitus,” Nature Reviews Endocrinology 20, no. 1 (2024): 27–49.

[23] S. Le Lay and P. E. Scherer, “Exploring Adipose Tissue-Derived Extracellular Vesicles in Inter-Organ Crosstalk: Implications for Metabolic Regulation and Adipose Tissue Function,” Cell Reports 44, no. 6 (2025): 115732.

[24] G. Mincheva, V. Felipo, V. Moreno-Manzano, et al., “Extracellular Vesicles From Mesenchymal Stem Cells Alter Gut Microbiota and Improve Neuroinflammation and Motor Impairment in Rats With Mild Liver Damage,” Neurotherapeutics 21, no. 6 (2024): e00445.

[25] B. Zhao, J. Wei, Z. Jiang, et al., “Mesenchymal Stem Cell-Derived Exosomes: An Emerging Therapeutic Strategy for Hepatic Ischemia-Reperfusion Injury,” Stem Cell Research & Therapy 16, no. 1 (2025): 178.

[26] C. Ma, J. Wang, X. Song, et al., “Molecular Mechanisms and Clinical Applications of Gut Microbiota-Derived Bioactive Compounds in Metabolic Dysfunction-Associated Fatty Liver Disease,” Frontiers in Immunology 16 (2025): 1682755.

[27] J. Zhao, L. Liu, Y. Y. Cao, et al., “MAFLD as Part of Systemic Metabolic Dysregulation,” Hepatology International 18, no. Suppl 2 (2024): 834–847.

[28] N. Kubota, T. Kubota, E. Kajiwara, et al., “Differential Hepatic Distribution of Insulin Receptor Substrates Causes Selective Insulin Resistance in Diabetes and Obesity,” Nature Communications 7 (2016): 12977.

[29] T. Hörbelt, B. Knebel, P. Fahlbusch, et al., “The Adipokine sFRP4 Induces Insulin Resistance and Lipogenesis in the Liver,” Biochimica et Biophysica Acta-molecular Basis of Disease 1865, no. 10 (2019): 2671–2684.

[30] B. He, K. D. Copps, O. Stöhr, et al., “Spatial Regulation of Glucose and Lipid Metabolism by Hepatic Insulin Signaling,” Cell Metabolism 37, no. 7 (2025): 1568–1583.e1567.

[31] S. C. Pal, M. Eslam, and N. Mendez-Sanchez, “Detangling the Interrelations Between MAFLD, Insulin Resistance, and Key Hormones,” Hormones 21, no. 4 (2022): 573–589.

[32] J. R. Cook, M. A. Hawkins, and U. B. Pajvani, “Liver Insulinization as a Driver of Triglyceride Dysmetabolism,” Nature Metabolism 5, no. 7 (2023): 1101–1110.

[33] W. Huang, S. Li, J. Su, et al., “High-Intensity Interval Training Induces Lactate Dehydrogenase B Lactylation to Inhibit Hepatic Lipogenesis to Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease,” Diabetes Obesity & Metabolism 28, no. 5 (2026): 3664–3680.

[34] S. Li, R. Liu, Q. Pan, et al., “De Novo Lipogenesis Is Elicited Dramatically in Human Hepatocellular Carcinoma Especially in Hepatitis C Virus-Induced Hepatocellular Carcinoma,” MedComm 1, no. 2 (2020): 178–187.

[35] N. Liu, J. Tian, C. J. Steer, et al., “MicroRNA-206-3p Suppresses Hepatic Lipogenesis and Cholesterol Synthesis While Driving Cholesterol Efflux,” Hepatology 81, no. 1 (2025): 111–125.

[36] J. Heeren and L. Scheja, “Metabolic-Associated Fatty Liver Disease and Lipoprotein Metabolism,” Molecular Metabolism 50 (2021): 101238.

[37] D. Q. Huang, V. W. S. Wong, M. E. Rinella, et al., “Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults,” Nature Reviews Disease Primers 11, no. 1 (2025): 14.

[38] M. C. Petersen and G. I. Shulman, “Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance,” Trends in Pharmacological Sciences 38, no. 7 (2017): 649–665.

[39] Y. Wang, J. S. Fleishman, T. Li, et al., “Pharmacological Therapy of Metabolic Dysfunction-Associated Steatotic Liver Disease-Driven Hepatocellular Carcinoma,” Frontiers in Pharmacology 14 (2023): 1336216.

[40] G. Musso, M. Cassader, E. Paschetta, et al., “Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis,” Gastroenterology 155, no. 2 (2018): 282–302.e288.

[41] S. Y. Avcioglu and C. Berkel, “Bile Acids and Bile Acid Metabolites in the Activation and Inhibition of Pyroptotic Cell Death, Influencing Inflammation,” Apmis 133, no. 9 (2025): e70066.

[42] P. Rada, Á. González-Rodríguez, C. García-Monzón, et al., “Understanding Lipotoxicity in NAFLD Pathogenesis: Is CD36 a Key Driver?,” Cell Death & Disease 11, no. 9 (2020): 802.

[43] E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, “The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD),” Metabolism 65, no. 8 (2016): 1038–1048.

[44] Z. Zakaria, Z. A. Othman, J. Bagi Suleiman, et al., “Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation,” Veterinary Sciences 8, no. 11 (2021): 274.

[45] K. Clare, J. F. Dillon, and P. N. Brennan, “Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD,” Journal of Clinical And Translational Hepatology 10, no. 5 (2022): 939–946.

[46] D. Bhattacharya, S. Kaushal, B. Chakraborty, et al., “Zebrafish Model of Palmitic Acid Induced MAFLD Recapitulates Pathways Conserved in Mice and Humans,” Scientific Reports 15, no. 1 (2025): 33343.

[47] L. Li, Z. Guo, Y. Zhao, et al., “The Impact of Oxidative Stress on Abnormal Lipid Metabolism-Mediated Disease Development,” Archives of Biochemistry And Biophysics 766 (2025): 110348.

[48] J. Aubert, K. Begriche, L. Knockaert, et al., “Increased Expression of Cytochrome P450 2E1 in Nonalcoholic Fatty Liver Disease: Mechanisms and Pathophysiological Role,” Clinics and Research in Hepatology and Gastroenterology 35, no. 10 (2011): 630–637.

[49] O. Krenkel and F. Tacke, “Liver Macrophages in Tissue Homeostasis and Disease,” Nature Reviews Immunology 17, no. 5 (2017): 306–321.

[50] R. Ramanathan, S. A. Patwa, A. H. Ali, et al., “Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD),” Cells 12, no. 24 (2023): 2806.

[51] S. H. Ibrahim, P. Hirsova, and G. J. Gores, “Non-Alcoholic Steatohepatitis Pathogenesis: Sublethal Hepatocyte Injury as a Driver of Liver Inflammation,” Gut 67, no. 5 (2018): 963–972.

[52] J. I. Beier and J. M. Banales, “Pyroptosis: An Inflammatory Link Between NAFLD and NASH With Potential Therapeutic Implications,” Journal of Hepatology 68, no. 4 (2018): 643–645.

[53] K. Tostes, A. C. Dos Santos, L. O. Alves, et al., “Autophagy Deficiency Abolishes Liver Mitochondrial DNA Segregation,” Autophagy 18, no. 10 (2022): 2397–2408.

[54] Y. Gao, Y. Wang, H. Liu, et al., “Mitochondrial DNA From Hepatocytes Induces Upregulation of Interleukin-33 Expression of Macrophages in Nonalcoholic Steatohepatitis,” Digestive And Liver Disease 52, no. 6 (2020): 637–643.

[55] C. Celik, S. Y. T. Lee, W. S. Yap, et al., “Endoplasmic Reticulum Stress and Lipids in Health and Diseases,” Progress in Lipid Research 89 (2023): 101198.

[56] C. Lebeaupin, D. Vallée, Y. Hazari, et al., “Endoplasmic Reticulum Stress Signalling and the Pathogenesis of Non-Alcoholic Fatty Liver Disease,” Journal of Hepatology 69, no. 4 (2018): 927–947.

[57] A. Stilkerich, G. Schicht, L. Seidemann, et al., “Cell Homeostasis or Cell Death-The Balancing Act Between Autophagy and Apoptosis Caused by Steatosis-Induced Endoplasmic Reticulum (ER) Stress,” Cells 14, no. 6 (2025): 449.

[58] H. Xu, Z. Wu, J. Qin, et al., “Stressed Hepatocyte Sustains Alcohol-Associated Hepatitis Progression by Producing Leukocyte Cell-Derived Chemotaxin 2,” Gut 74, no. 8 (2025): 1321–1334.

[59] G. Barrera, S. Pizzimenti, M. Daga, et al., “Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders,” Antioxidants (Basel) 7, no. 8 (2018): 102.

[60] S. Pelusi, A. Cespiati, R. Rametta, et al., “Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis,” Clinical Gastroenterology and Hepatology 17, no. 11 (2019): 2310–2319.e2316.

[61] C. Koliaki, J. Szendroedi, K. Kaul, et al., “Adaptation of Hepatic Mitochondrial Function in Humans With Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis,” Cell Metabolism 21, no. 5 (2015): 739–746.

[62] J. Li, T. N. Sapper, E. Mah, et al., “Green Tea Extract Provides Extensive Nrf2-Independent Protection Against Lipid Accumulation and NFκB Pro- Inflammatory Responses During Nonalcoholic Steatohepatitis in Mice Fed a High-Fat Diet,” Molecular Nutrition & Food Research 60, no. 4 (2016): 858–870.

[63] P. Torre, B. M. Motta, R. Sciorio, et al., “Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System,” Frontiers in Medicine 8 (2021): 781567.

[64] E. Seki and R. F. Schwabe, “Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways,” Hepatology 61, no. 3 (2015): 1066–1079.

[65] P. N. Newsome and R. Loomba, “Therapeutic Horizons in Metabolic Dysfunction-Associated Steatohepatitis,” Journal of Clinical Investigation 135, no. 13 (2025): e186425.

[66] L. Zhang, M. Wang, R. An, et al., “Activation of NLRP3 Inflammasome via Drp1 Overexpression in Kupffer Cells Aggravates Ischemia-Reperfusion Injury in Hepatic Steatosis,” Journal of Clinical and Translational Hepatology 11, no. 5 (2023): 1069–1078.

[67] M. Pizzuto, P. Pelegrin, and J. M. Ruysschaert, “Lipid-Protein Interactions Regulating the Canonical and the Non-Canonical NLRP3 Inflammasome,” Progress in Lipid Research 87 (2022): 101182.

[68] S. Hamamah, O. C. Iatcu, and M. Covasa, “Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD),” Nutrients 17, no. 1 (2024): 143.

[69] H. Jain, A. Kumar, S. Almousa, et al., “Characterisation of LPS+ Bacterial Extracellular Vesicles Along the Gut-Hepatic Portal Vein-Liver Axis,” Journal of Extracellular Vesicles 13, no. 7 (2024): e12474.

[70] X. Lv, C. Nie, Y. Shi, et al., “Ergothioneine Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Enhancing Autophagy, Inhibiting Oxidative Damage and Inflammation,” Lipids in Health and Disease 23, no. 1 (2024): 395.

[71] I. D. Vachliotis and S. A. Polyzos, “The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review,” Current Obesity Reports 14, no. 1 (2025): 65.

[72] D. G. Le Couteur, M. C. Ngu, N. J. Hunt, et al., “Liver, Ageing and Disease,” Nature Reviews Gastroenterology & Hepatology 22, no. 10 (2025): 680–695.

[73] W. Qin and J. Weng, “Hepatocyte NLRP3 Interacts With PKCε to Drive Hepatic Insulin Resistance and Steatosis,” Science Bulletin 68, no. 13 (2023): 1413–1429.

[74] J. Xu, S. Chen, W. Wang, et al., “Hepatic CDP-Diacylglycerol Synthase 2 Deficiency Causes Mitochondrial Dysfunction and Promotes Rapid Progression of NASH and Fibrosis,” Science Bulletin 67, no. 3 (2022): 299–314.

[75] E. Rebelos, P. Iozzo, M. A. Guzzardi, et al., “Brain-Gut-Liver Interactions Across the Spectrum of Insulin Resistance in Metabolic Fatty Liver Disease,” World Journal of Gastroenterology 27, no. 30 (2021): 4999–5018.

[76] A. Armandi and J. M. Schattenberg, “Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches,” Nutrients 13, no. 6 (2021): 1977.

[77] G. S. Hotamisligil, “Inflammation, Metaflammation and Immunometabolic Disorders,” Nature 542, no. 7640 (2017): 177–185.

[78] C. Boutari, P. Lefkos, V. G. Athyros, et al., “Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications,” Current Vascular Pharmacology 16, no. 3 (2018): 214–218.

[79] C. J. David and J. Massagué, “Contextual Determinants of TGFβ Action in Development, Immunity and Cancer,” Nature Reviews Molecular Cell Biology 19, no. 7 (2018): 419–435.

[80] K. W. Finnson, Y. Almadani, and A. Philip, “Non-Canonical (non-SMAD2/3) TGF-β Signaling in Fibrosis: Mechanisms and Targets,” Seminars in Cell & Developmental Biology 101 (2020): 115–122.

[81] X. J. Mi, J. G. Hou, S. Jiang, et al., “Maltol Mitigates Thioacetamide-Induced Liver Fibrosis Through TGF-β1-Mediated Activation of PI3K/Akt Signaling Pathway,” Journal of Agricultural And Food Chemistry 67, no. 5 (2019): 1392–1401.

[82] Y. Zhao, M. F. Zhao, S. Jiang, et al., “Liver Governs Adipose Remodelling via Extracellular Vesicles in Response to Lipid Overload,” Nature Communications 11, no. 1 (2020): 719.

[83] I. Mederacke, C. C. Hsu, J. S. Troeger, et al., “Fate Tracing Reveals Hepatic Stellate Cells as Dominant Contributors to Liver Fibrosis Independent of Its Aetiology,” Nature Communications 4 (2013): 2823.

[84] M. E. Rinella, F. Tacke, A. J. Sanyal, et al., “Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD,” Journal of Hepatology 71, no. 4 (2019): 823–833.

[85] I. Vachliotis, A. Goulas, P. Papaioannidou, et al., “Nonalcoholic Fatty Liver Disease: Lifestyle and Quality of Life,” Hormones (Athens) 21, no. 1 (2022): 41–49.

[86] W. N. Hannah Jr. and S. A. Harrison, “Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease,” Clinics in Liver Disease 20, no. 2 (2016): 339–350.

[87] H. Toplak, R. Stauber, and H. Sourij, “EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease,” Diabetologia 59, no. 6 (2016): 1121–1140.

[88] B. A. Neuschwander-Tetri, “Therapeutic Landscape for NAFLD in 2020,” Gastroenterology 158, no. 7 (2020): 1984–1998.e1983.

[89] R. Loomba, Z. Kayali, M. Noureddin, et al., “GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease,” Gastroenterology 155, no. 5 (2018): 1463–1473.e1466.

[90] E. J. Lawitz, A. Coste, F. Poordad, et al., “Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis,” Clinical Gastroenterology And Hepatology 16, no. 12 (2018): 1983–1991.e1983.

[91] Z. M. Younossi, V. Ratziu, R. Loomba, et al., “Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis From a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial,” Lancet 394, no. 10215 (2019): 2184–2196.

[92] F. Bril, S. Kalavalapalli, V. C. Clark, et al., “Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes,” Clinical Gastroenterology And Hepatology 16, no. 4 (2018): 558–566.e552.

[93] S. M. Francque, P. Bedossa, V. Ratziu, et al., “A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH,” New England Journal of Medicine 385, no. 17 (2021): 1547–1558.

[94] P. M. O'Neil, A. L. Birkenfeld, B. McGowan, et al., “Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: A Randomised, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial,” Lancet 392, no. 10148 (2018): 637–649.

[95] P. N. Newsome, K. Buchholtz, K. Cusi, et al., “A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis,” New England Journal of Medicine 384, no. 12 (2021): 1113–1124.

[96] S. A. Harrison, V. W. Wong, T. Okanoue, et al., “Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results From Randomized Phase III STELLAR Trials,” Journal of Hepatology 73, no. 1 (2020): 26–39.

[97] N. Chalasani, Z. Younossi, J. E. Lavine, et al., “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases,” Hepatology 67, no. 1 (2018): 328–357.

[98] Y. Sumida, M. Yoneda, Y. Seko, et al., “Role of Vitamin E in the Treatment of Non-Alcoholic Steatohepatitis,” Free Radical Biology And Medicine 177 (2021): 391–403.

[99] J. Zhao, Y. Peng, H. Lei, et al., “Autocrine Netrin-1 Signaling in Hepatic Stellate Cells Drives Liver Fibrosis and Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis in Mice,” Advanced Science 13, no. 10 (2026): e14545.

[100] Y. W. Shi and J. G. Fan, “Current Status and Challenges in the Drug Treatment for Fibrotic Nonalcoholic Steatohepatitis,” Acta Pharmacologica Sinica 43, no. 5 (2022): 1191–1199.

[101] J. M. Fraile, S. Palliyil, C. Barelle, et al., “Non-Alcoholic Steatohepatitis (NASH)—A Review of a Crowded Clinical Landscape, Driven by a Complex Disease,” Drug Design Development And Therapy 15 (2021): 3997–4009.

[102] H. Ledford, “First US Drug Approved for a Liver Disease Surging Around the World,” Nature (2024), https://doi.org/10.1038/d41586-024-00747-9.

[103] Y. Yin, H. Chen, Y. Wang, et al., “Roles of Extracellular Vesicles in the Aging Microenvironment and Age-Related Diseases,” Journal of Extracellular Vesicles 10, no. 12 (2021): e12154.

[104] M. A. Kumar, S. K. Baba, H. Q. Sadida, et al., “Extracellular Vesicles as Tools and Targets in Therapy for Diseases,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 27.

[105] W. Chang and J. Wang, “Exosomes and Their Noncoding RNA Cargo Are Emerging as New Modulators for Diabetes Mellitus,” Cells 8, no. 8 (2019): 853.

[106] X. He, G. Kuang, Y. Wu, et al., “Emerging Roles of Exosomal miRNAs in Diabetes Mellitus,” Clinical and Translational Medicine 11, no. 6 (2021): e468.

[107] S. Soltani, K. Mansouri, S. Parvaneh, et al., “Diabetes Complications and Extracellular Vesicle Therapy,” Reviews in Endocrine & Metabolic Disorders 23, no. 3 (2022): 357–385.

[108] M. Ghafourian, R. Mahdavi, Z. Akbari Jonoush, et al., “The Implications of Exosomes in Pregnancy: Emerging as New Diagnostic Markers and Therapeutics Targets,” Cell Communication and Signaling 20, no. 1 (2022): 51.

[109] J. Wang, L. Li, Z. Zhang, et al., “Extracellular Vesicles Mediate the Communication of Adipose Tissue With Brain and Promote Cognitive Impairment Associated With Insulin Resistance,” Cell Metabolism 34, no. 9 (2022): 1264–1279.e1268.

[110] Y. Sun, H. Shi, S. Yin, et al., “Human Mesenchymal Stem Cell Derived Exosomes Alleviate Type 2 Diabetes Mellitus by Reversing Peripheral Insulin Resistance and Relieving β-Cell Destruction,” ACS Nano 12, no. 8 (2018): 7613–7628.

[111] L. Shen, J. Ma, S. Liang, et al., “Cooked Meat-Derived Extracellular Vesicles Ssc-miR-1 Induces Metabolic Disorders in the Mice Liver via PI3k/AKT Pathway,” Npj Science of Food 10, no. 1 (2026): 59.

[112] J. Duan, Z. Huang, S. Qin, et al., “Oxidative Stress Induces Extracellular Vesicle Release by Upregulation of HEXB to Facilitate Tumour Growth in Experimental Hepatocellular Carcinoma,” Journal of Extracellular Vesicles 13, no. 7 (2024): e12468.

[113] M. Yáñez-Mó, P. R. Siljander, Z. Andreu, et al., “Biological Properties of Extracellular Vesicles and Their Physiological Functions,” Journal of Extracellular Vesicles 4 (2015): 27066.

[114] R. Kalluri and V. S. LeBleu, “The Biology, Function, and Biomedical Applications of Exosomes,” Science 367, no. 6478 (2020): eaau6977.

[115] G. Raposo and W. Stoorvogel, “Extracellular Vesicles: Exosomes, Microvesicles, and Friends,” Journal of Cell Biology 200, no. 4 (2013): 373–383.

[116] O. J. Arntz, B. C. Pieters, M. C. Oliveira, et al., “Oral Administration of Bovine Milk Derived Extracellular Vesicles Attenuates Arthritis in Two Mouse Models,” Molecular Nutrition & Food Research 59, no. 9 (2015): 1701–1712.

[117] Q. Hu, C. J. Lyon, J. K. Fletcher, et al., “Extracellular Vesicle Activities Regulating Macrophage- and Tissue-Mediated Injury and Repair Responses,” Acta Pharmaceutica Sinica B 11, no. 6 (2021): 1493–1512.

[118] R. Ogawa, C. Tanaka, M. Sato, et al., “Adipocyte-Derived Microvesicles Contain RNA That Is Transported Into Macrophages and Might be Secreted Into Blood Circulation,” Biochemical and Biophysical Research Communications 398, no. 4 (2010): 723–729.

[119] S. C. Ferrante, E. P. Nadler, D. K. Pillai, et al., “Adipocyte-Derived Exosomal miRNAs: A Novel Mechanism for Obesity-Related Disease,” Pediatric Research 77, no. 3 (2015): 447–454.

[120] A. Constantin, A. Filippi, N. Alexandru, et al., “Extracellular Vesicles From Adipose Tissue Stem Cells in Diabetes and Associated Cardiovascular Disease; Pathobiological Impact and Therapeutic Potential,” International Journal of Molecular Sciences 21, no. 24 (2020): 9598.

[121] X. Yang, J. Hao, J. Luo, et al., “Adipose Tissue-Derived Extracellular Vesicles: Systemic Messengers in Health and Disease (Review),” Molecular Medicine Reports 28, no. 4 (2023): 189.

[122] G. Berumen Sánchez, K. E. Bunn, H. H. Pua, et al., “Extracellular Vesicles: Mediators of Intercellular Communication in Tissue Injury and Disease,” Cell Communication and Signaling 19, no. 1 (2021): 104.

[123] X. Zhang, X. Ji, Q. Wang, et al., “New Insight Into Inter-Organ Crosstalk Contributing to the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD),” Protein & Cell 9, no. 2 (2018): 164–177.

[124] Y. Li, J. Wu, R. Liu, et al., “Extracellular Vesicles: Catching the Light of Intercellular Communication in Fibrotic Liver Diseases,” Theranostics 12, no. 16 (2022): 6955–6971.

[125] A. Hoshino, B. Costa-Silva, T. L. Shen, et al., “Tumour Exosome Integrins Determine Organotropic Metastasis,” Nature 527, no. 7578 (2015): 329–335.

[126] B. Costa-Silva, N. M. Aiello, A. J. Ocean, et al., “Pancreatic Cancer Exosomes Initiate Pre-Metastatic Niche Formation in the Liver,” Nature Cell Biology 17, no. 6 (2015): 816–826.

[127] K. Sato, F. Meng, S. Glaser, et al., “Exosomes in Liver Pathology,” Journal of Hepatology 65, no. 1 (2016): 213–221.

[128] M. Mathieu, L. Martin-Jaular, G. Lavieu, et al., “Specificities of Secretion and Uptake of Exosomes and Other Extracellular Vesicles for Cell-To-Cell Communication,” Nature Cell Biology 21, no. 1 (2019): 9–17.

[129] M. A. Mori, R. G. Ludwig, R. Garcia-Martin, et al., “Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease,” Cell Metabolism 30, no. 4 (2019): 656–673.

[130] S. Zhang, Q. Wang, D. E. L. Tan, et al., “Gut-Liver Axis: Potential Mechanisms of Action of Food-Derived Extracellular Vesicles,” Journal of Extracellular Vesicles 13, no. 6 (2024): e12466.

[131] J. Cao, S. Qin, B. Li, et al., “Extracellular Vesicle-Induced Lipid Dysregulation Drives Liver Premetastatic Niche Formation in Colorectal Cancer,” Gut 74, no. 12 (2025): 2012–2023.

[132] F. Yang, B. Ni, X. Liang, et al., “Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Nanotherapeutics for Concanavalin A-Induced Hepatitis: Modulating the Gut-Liver Axis,” Stem Cell Research & Therapy 16, no. 1 (2025): 4.

[133] R. Sabaratnam, J. F. P. Wojtaszewski, and K. Højlund, “Factors Mediating Exercise-Induced Organ Crosstalk,” Acta Physiologica 234, no. 2 (2022): e13766.

[134] M. Whitham, B. L. Parker, M. Friedrichsen, et al., “Extracellular Vesicles Provide a Means for Tissue Crosstalk During Exercise,” Cell Metabolism 27, no. 1 (2018): 237–251.e234.

[135] G. Zhang, X. Huang, H. Xiu, et al., “Extracellular Vesicles: Natural Liver-Accumulating Drug Delivery Vehicles for the Treatment of Liver Diseases,” Journal of Extracellular Vesicles 10, no. 2 (2020): e12030.

[136] Z. Weng, B. Zhang, C. Wu, et al., “Therapeutic Roles of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Cancer,” Journal of Hematology & Oncology 14, no. 1 (2021): 136.

[137] C. Gardin, L. Ferroni, G. Bellin, et al., “Therapeutic Potential of Autologous Adipose-Derived Stem Cells for the Treatment of Liver Disease,” International Journal of Molecular Sciences 19, no. 12 (2018): 4064.

[138] C. Y. Chen, S. S. Rao, T. Yue, et al., “Glucocorticoid-Induced Loss of Beneficial Gut Bacterial Extracellular Vesicles Is Associated With the Pathogenesis of Osteonecrosis,” Science Advances 8, no. 15 (2022): eabg8335.

[139] N. Díaz-Garrido, J. Badia, and L. Baldomà, “Microbiota-Derived Extracellular Vesicles in Interkingdom Communication in the Gut,” Journal of Extracellular Vesicles 10, no. 13 (2021): e12161.

[140] Q. Li, B. Li, Q. Zhang, et al., “Extracellular Vesicles From Limosilactobacillus Johnsonii Enhance Milk Fat Synthesis by Inducing CD36 Dynamic Palmitoylation and Activating PPARγ Signalling,” Journal of Extracellular Vesicles 14, no. 8 (2025): e70143.

[141] M. Li, H. Huang, X. Wei, et al., “Clinical Investigation on Nebulized Human Umbilical Cord MSC-Derived Extracellular Vesicles for Pulmonary Fibrosis Treatment,” Signal Transduction And Targeted Therapy 10, no. 1 (2025): 179.

[142] L. Tong, S. Zhang, Q. Liu, et al., “Milk-Derived Extracellular Vesicles Protect Intestinal Barrier Integrity in the Gut-Liver Axis,” Science Advances 9, no. 15 (2023): eade5041.

[143] A. Khoo, M. Govindarajan, Z. Qiu, et al., “Prostate Cancer Reshapes the Secreted and Extracellular Vesicle Urinary Proteomes,” Nature Communications 15, no. 1 (2024): 5069.

[144] R. Liam-Or, F. N. Faruqu, A. Walters, et al., “Cellular Uptake and in Vivo Distribution of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Are Protein Corona Dependent,” Nature Nanotechnology 19, no. 6 (2024): 846–855.

[145] M. Q. Lian, W. H. Chng, J. Liang, et al., “Plant-Derived Extracellular Vesicles: Recent Advancements and Current Challenges on Their Use for Biomedical Applications,” Journal of Extracellular Vesicles 11, no. 12 (2022): e12283.

[146] M. Tkach and C. Théry, “Communication by Extracellular Vesicles: Where We Are and Where We Need to Go,” Cell 164, no. 6 (2016): 1226–1232.

[147] G. van Niel, G. D'Angelo, and G. Raposo, “Shedding Light on the Cell Biology of Extracellular Vesicles,” Nature Reviews Molecular Cell Biology 19, no. 4 (2018): 213–228.

[148] M. Colombo, G. Raposo, and C. Théry, “Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles,” Annual Review of Cell And Developmental Biology 30 (2014): 255–289.

[149] C. Zhang, T. Jiang, G. Jiang, et al., “White Adipose Tissue-Derived Small Extracellular Vesicles: A New Potential Therapeutic Reagent for Accelerating Diabetic Wound Healing,” Faseb Journal 37, no. 12 (2023): e23314.

[150] Z. G. Wang, Z. Y. He, S. Liang, et al., “Comprehensive Proteomic Analysis of Exosomes Derived From Human Bone Marrow, Adipose Tissue, and Umbilical Cord Mesenchymal Stem Cells,” Stem Cell Research & Therapy 11, no. 1 (2020): 511.

[151] D. Sun, S. Mou, L. Chen, et al., “High Yield Engineered Nanovesicles From ADSC With Enriched miR-21-5p Promote Angiogenesis in Adipose Tissue Regeneration,” Biomaterials Research 26, no. 1 (2022): 83.

[152] J. A. Martínez-Greene, M. Gómez-Chavarín, M. D. P. Ramos-Godínez, et al., “Isolation of Hepatic and Adipose-Tissue-Derived Extracellular Vesicles Using Density Gradient Separation and Size Exclusion Chromatography,” International Journal of Molecular Sciences 24, no. 16 (2023): 12704.

[153] Q. Zou, M. Zhang, R. Yuan, et al., “Small Extracellular Vesicles Derived From Dermal Fibroblasts Promote Fibroblast Activity and Skin Development Through Carrying miR-218 and ITGBL1,” Journal of Nanobiotechnology 20, no. 1 (2022): 296.

[154] J. Phelps, D. A. Hart, A. P. Mitha, et al., “Physiological Oxygen Conditions Enhance the Angiogenic Properties of Extracellular Vesicles From Human Mesenchymal Stem Cells,” Stem Cell Research & Therapy 14, no. 1 (2023): 218.

[155] R. Skovronova, E. Scaccia, I. C. S. Calcat, et al., “Adipose Stromal Cells Bioproducts as Cell-Free Therapies: Manufacturing and Therapeutic Dose Determine in Vitro Functionality,” Journal of Translational Medicine 21, no. 1 (2023): 723.

[156] Z. Cui, F. K. Amevor, X. Zhao, et al., “Potential Therapeutic Effects of Milk-Derived Exosomes on Intestinal Diseases,” Journal of Nanobiotechnology 21, no. 1 (2023): 496.

[157] C. Théry, K. W. Witwer, E. Aikawa, et al., “Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines,” Journal of Extracellular Vesicles 7, no. 1 (2018): 1535750.

[158] T. L. Ramos, L. I. Sánchez-Abarca, and S. Muntión, “MSC Surface Markers (CD44, CD73, and CD90) Can Identify Human MSC-Derived Extracellular Vesicles by Conventional Flow Cytometry,” Cell Communication and Signaling 14 (2016): 2.

[159] H. Li, Y. Ding, J. Huang, et al., “Angiopep-2 Modified Exosomes Load Rifampicin With Potential for Treating Central Nervous System Tuberculosis,” International Journal of Nanomedicine 18 (2023): 489–503.

[160] B. Dong, C. Wang, J. Zhang, et al., “Exosomes From Human Umbilical Cord Mesenchymal Stem Cells Attenuate the Inflammation of Severe Steroid-Resistant Asthma by Reshaping Macrophage Polarization,” Stem Cell Research & Therapy 12, no. 1 (2021): 204.

[161] P. Siwaponanan, P. Kaewkumdee, W. Phromawan, et al., “Increased Expression of Six-Large Extracellular Vesicle-Derived miRNAs Signature for Nonvalvular Atrial Fibrillation,” Journal of Translational Medicine 20, no. 1 (2022): 4.

[162] E. Lozano-Andrés, S. F. Libregts, V. Toribio, et al., “Tetraspanin-Decorated Extracellular Vesicle-Mimetics as a Novel Adaptable Reference Material,” Journal of Extracellular Vesicles 8, no. 1 (2019): 1573052.

[163] M. Dehghani and T. R. Gaborski, “Fluorescent Labeling of Extracellular Vesicles,” Methods in Enzymology 645 (2020): 15–42.

[164] N. Kamei, H. Nishimura, A. Matsumoto, et al., “Comparative Study of Commercial Protocols for High Recovery of High-Purity Mesenchymal Stem Cell-Derived Extracellular Vesicle Isolation and Their Efficient Labeling With Fluorescent Dyes,” Nanomedicine 35 (2021): 102396.

[165] Q. Peng, J. Zhang, and G. Zhou, “Circulating Exosomes Regulate T-Cell-Mediated Inflammatory Response in Oral Lichen Planus,” Journal of Oral Pathology and Medicine 48, no. 2 (2019): 143–150.

[166] M. Ross, H. Atalla, N. Karrow, et al., “The Bioactivity of Colostrum and Milk Exosomes of High, Average, and Low Immune Responder Cows on Human Intestinal Epithelial Cells,” Journal of Dairy Science 104, no. 3 (2021): 2499–2510.

[167] K. Takov, D. M. Yellon, and S. M. Davidson, “Confounding Factors in Vesicle Uptake Studies Using Fluorescent Lipophilic Membrane Dyes,” Journal of Extracellular Vesicles 6, no. 1 (2017): 1388731.

[168] S. Wei, L. Peng, J. Yang, et al., “Exosomal Transfer of miR-15b-3p Enhances Tumorigenesis and Malignant Transformation Through the DYNLT1/Caspase-3/Caspase-9 Signaling Pathway in Gastric Cancer,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 32.

[169] C. Lässer, V. S. Alikhani, K. Ekström, et al., “Human Saliva, Plasma and Breast Milk Exosomes Contain RNA: Uptake by Macrophages,” Journal of Translational Medicine 9 (2011): 9.

[170] V. V. T. Nguyen, S. Ye, V. Gkouzioti, et al., “A Human Kidney and Liver Organoid-Based Multi-Organ-On-A-Chip Model to Study the Therapeutic Effects and Biodistribution of Mesenchymal Stromal Cell-Derived Extracellular Vesicles,” Journal of Extracellular Vesicles 11, no. 11 (2022): e12280.

[171] Y. Mateo-Otero, M. Yeste, J. Roca, et al., “Seminal Extracellular Vesicles Subsets Modulate Gene Expression in Cumulus Cells of Porcine in Vitro Matured Oocytes,” Scientific Reports 12, no. 1 (2022): 19096.

[172] W. Jiang, T. Zhang, Y. Qiu, et al., “Keratinocyte-To-Macrophage Communication Exacerbate Psoriasiform Dermatitis via LRG1-Enriched Extracellular Vesicles,” Theranostics 14, no. 3 (2024): 1049–1064.

[173] M. T. Sultan, B. Y. Choi, O. Ajiteru, et al., “Reinforced-Hydrogel Encapsulated hMSCs Towards Brain Injury Treatment by Trans-Septal Approach,” Biomaterials 266 (2021): 120413.

[174] M. Durak-Kozica, Z. Baster, K. Kubat, et al., “3D Visualization of Extracellular Vesicle Uptake by Endothelial Cells,” Cellular & Molecular Biology Letters 23 (2018): 57.

[175] V. Azzu, M. Vacca, S. Virtue, et al., “Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease,” Gastroenterology 158, no. 7 (2020): 1899–1912.

[176] J. M. Sabio and C. Crewe, “Isolation of Adipose Tissue Extracellular Vesicles,” Methods in Molecular Biology 2662 (2023): 209–217.

[177] N. Akbar, V. Azzimato, R. P. Choudhury, et al., “Extracellular Vesicles in Metabolic Disease,” Diabetologia 62, no. 12 (2019): 2179–2187.

[178] K. Göran Ronquist, “Extracellular Vesicles and Energy Metabolism,” Clinica Chimica Acta 488 (2019): 116–121.

[179] P. Hirsova, S. H. Ibrahim, A. Krishnan, et al., “Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes,” Gastroenterology 150, no. 4 (2016): 956–967.

[180] T. Thomou, M. A. Mori, J. M. Dreyfuss, et al., “Adipose-Derived Circulating miRNAs Regulate Gene Expression in Other Tissues,” Nature 542, no. 7642 (2017): 450–455.

[181] C. Yan, X. Tian, J. Li, et al., “A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development in Vivo,” Diabetes 70, no. 2 (2021): 577–588.

[182] E. S. Koeck, T. Iordanskaia, S. Sevilla, et al., “Adipocyte Exosomes Induce Transforming Growth Factor Beta Pathway Dysregulation in Hepatocytes: A Novel Paradigm for Obesity-Related Liver Disease,” Journal of Surgical Research 192, no. 2 (2014): 268–275.

[183] D. Li, H. Song, L. Shuo, et al., “Gonadal White Adipose Tissue-Derived Exosomal MiR-222 Promotes Obesity-Associated Insulin Resistance,” Aging 12, no. 22 (2020): 22719–22743.

[184] J. Xu, L. Cui, J. Wang, et al., “Cold-Activated Brown Fat-Derived Extracellular Vesicle-miR-378a-3p Stimulates Hepatic Gluconeogenesis in Male Mice,” Nature Communications 14, no. 1 (2023): 5480.

[185] W. Ying, M. Riopel, G. Bandyopadhyay, et al., “Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate in Vivo and in Vitro Insulin Sensitivity,” Cell 171, no. 2 (2017): 372–384.e312.

[186] T. Watanabe, A. Tsuchiya, S. Takeuchi, et al., “Development of a Non-Alcoholic Steatohepatitis Model With Rapid Accumulation of Fibrosis, and Its Treatment Using Mesenchymal Stem Cells and Their Small Extracellular Vesicles,” Regenerative Therapy 14 (2020): 252–261.

[187] A. Fuchs, D. Samovski, G. I. Smith, et al., “Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease,” Gastroenterology 161, no. 3 (2021): 968–981.e912.

[188] A. Blandin, J. Amosse, J. Froger, et al., “Extracellular Vesicles Are Carriers of Adiponectin With Insulin-Sensitizing and Anti-Inflammatory Properties,” Cell Reports 42, no. 8 (2023): 112866.

[189] X. Zhou, Z. Li, M. Qi, et al., “Brown Adipose Tissue-Derived Exosomes Mitigate the Metabolic Syndrome in High Fat Diet Mice,” Theranostics 10, no. 18 (2020): 8197–8210.

[190] B. Rong, R. Feng, C. Liu, et al., “Reduced Delivery of Epididymal Adipocyte-Derived Exosomal Resistin Is Essential for Melatonin Ameliorating Hepatic Steatosis in Mice,” Journal of Pineal Research 66, no. 4 (2019): e12561.

[191] M. E. Kranendonk, F. L. Visseren, J. A. van Herwaarden, et al., “Effect of Extracellular Vesicles of Human Adipose Tissue on Insulin Signaling in Liver and Muscle Cells,” obes 22, no. 10 (2014): 2216–2223.

[192] Y. Niitsu, C. Komiya, A. Takeuchi, et al., “Increased Serum Extracellular Vesicle miR-144-3p and miR-486a-3p in a Mouse Model of Adipose Tissue Regeneration Promote Hepatocyte Proliferation by Targeting Txnip,” PLoS One 18, no. 5 (2023): e0284989.

[193] Y. Kim, T. Son, J. Park, et al., “Role of Exosomes Derived From Adipose Tissue Under Obese Conditions in Skeletal Muscle and Liver Cells: Commonalities and Differences,” Molecular Nutrition & Food Research 66, no. 23 (2022): e2200358.

[194] C. Crewe, S. Chen, D. Bu, et al., “Deficient Caveolin-1 Synthesis in Adipocytes Stimulates Systemic Insulin-Independent Glucose Uptake via Extracellular Vesicles,” Diabetes 71, no. 12 (2022): 2496–2512.

[195] Y. Kariba, T. Yoshizawa, Y. Sato, et al., “Brown Adipocyte-Derived Exosomal miR-132-3p Suppress Hepatic Srebf1 Expression and Thereby Attenuate Expression of Lipogenic Genes,” Biochemical and Biophysical Research Communications 530, no. 3 (2020): 500–507.

[196] M. M. Lu, Y. Ren, Y. W. Zhou, et al., “Antagonizing Adipose Tissue-Derived Exosome miR-103-Hepatocyte Phosphatase and Tensin Homolog Pathway Alleviates Autophagy in Non-Alcoholic Steatohepatitis: A Trans-Cellular Crosstalk,” World Journal of Gastroenterology 29, no. 29 (2023): 4528–4541.

[197] S. Y. Dang, Y. Leng, Z. X. Wang, et al., “Exosomal Transfer of Obesity Adipose Tissue for Decreased miR-141-3p Mediate Insulin Resistance of Hepatocytes,” International Journal of Biological Sciences 15, no. 2 (2019): 351–368.

[198] Y. Li, Y. Luan, J. Li, et al., “Exosomal miR-199a-5p Promotes Hepatic Lipid Accumulation by Modulating MST1 Expression and Fatty Acid Metabolism,” Hepatology International 14, no. 6 (2020): 1057–1074.

[199] T. V. Rohm, F. C. G. Dos Reis, and E. R. K. Cunha, “Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice,” Gastroenterology 169, no. 4 (2025): 691–704.e699.

[200] Z. Wang, T. Ma, G. Bai, et al., “Adipose Tissue-Derived Extracellular Vesicles Loaded With miR-141-3p Regulate Obesity-Induced Insulin Resistance by Targeting Glycogen Synthesis and Gluconeogenesis,” International Journal of Nanomedicine 20 (2025): 5709–5726.

[201] B. Wu, J. Feng, J. Guo, et al., “ADSCs-Derived Exosomes Ameliorate Hepatic Fibrosis by Suppressing Stellate Cell Activation and Remodeling Hepatocellular Glutamine Synthetase-Mediated Glutamine and Ammonia Homeostasis,” Stem Cell Research & Therapy 13, no. 1 (2022): 494.

[202] H. Gu, K. Yang, Z. Shen, et al., “ER Stress-Induced Adipocytes Secrete-Aldo-Keto Reductase 1B7-Containing Exosomes That Cause Nonalcoholic Steatohepatitis in Mice,” Free Radical Biology and Medicine 163 (2021): 220–233.

[203] A. Lin and W. He, “LINC01705 Derived From Adipocyte Exosomes Regulates Hepatocyte Lipid Accumulation via an miR-552-3p/LXR Axis,” Journal of Diabetes Investigation 14, no. 10 (2023): 1160–1171.

[204] Y. Liu, J. Tan, S. Ou, et al., “Adipose-Derived Exosomes Deliver miR-23a/b to Regulate Tumor Growth in Hepatocellular Cancer by Targeting the VHL/HIF Axis,” Journal of Physiology and Biochemistry 75, no. 3 (2019): 391–401.

[205] H. Zhang, T. Deng, S. Ge, et al., “Exosome circRNA Secreted From Adipocytes Promotes the Growth of Hepatocellular Carcinoma by Targeting Deubiquitination-Related USP7,” Oncogene 38, no. 15 (2019): 2844–2859.

[206] H. Zhao, Q. Shang, Z. Pan, et al., “Exosomes From Adipose-Derived Stem Cells Attenuate Adipose Inflammation and Obesity Through Polarizing M2 Macrophages and Beiging in White Adipose Tissue,” Diabetes 67, no. 2 (2018): 235–247.

[207] Y. Gong, H. Dai, W. Liu, et al., “Exosomes Derived From Human Adipose-Derived Stem Cells Alleviate Hepatic Ischemia-Reperfusion (I/R) Injury Through the miR-183/ALOX5 Axis,” FASEB Journal 37, no. 3 (2023): e22782.

[208] Y. Jin, J. Wang, H. Li, et al., “Extracellular Vesicles Secreted by Human Adipose-Derived Stem Cells (hASCs) Improve Survival Rate of Rats With Acute Liver Failure by Releasing lncRNA H19,” EBioMedicine 34 (2018): 231–242.

[209] L. M. Domínguez, B. Bueloni, M. J. Cantero, et al., “Chromatographic Scalable Method to Isolate Engineered Extracellular Vesicles Derived From Mesenchymal Stem Cells for the Treatment of Liver Fibrosis in Mice,” International Journal of Molecular Sciences 24, no. 11 (2023): 9586.

[210] W. Xia, G. Lai, Y. Li, et al., “Photo-Crosslinked Adhesive Hydrogel Loaded With Extracellular Vesicles Promoting Hemostasis and Liver Regeneration,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1170212.

[211] L. Gan, L. Zheng, L. Yao, et al., “Exosomes From Adipose-Derived Mesenchymal Stem Cells Improve Liver Fibrosis by Regulating the miR-20a-5p/TGFBR2 Axis to Affect the p38 MAPK/NF-κB Pathway,” Cytokine 172 (2023): 156386.

[212] M. Shen, L. Zhou, X. Fan, et al., “Metabolic Reprogramming of CD4(+) T Cells by Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuates Autoimmune Hepatitis Through Mitochondrial Protein Transfer,” International Journal of Nanomedicine 19 (2024): 9799–9819.

[213] Z. Du, T. Wu, L. Liu, et al., “Extracellular Vesicles-Derived miR-150-5p Secreted by Adipose-Derived Mesenchymal Stem Cells Inhibits CXCL1 Expression to Attenuate Hepatic Fibrosis,” Journal of Cellular and Molecular Medicine 25, no. 2 (2021): 701–715.

[214] Y. Wang, C. Piao, T. Liu, et al., “Effects of the Exosomes of Adipose-Derived Mesenchymal Stem Cells on Apoptosis and Pyroptosis of Injured Liver in Miniature Pigs,” Biomedicine & Pharmacotherapy 169 (2023): 115873.

[215] Q. Zhang, C. Piao, H. Ma, et al., “Exosomes From Adipose-Derived Mesenchymal Stem Cells Alleviate Liver Ischaemia Reperfusion Injury Subsequent to Hepatectomy in Rats by Regulating Mitochondrial Dynamics and Biogenesis,” Journal of Cellular and Molecular Medicine 25, no. 21 (2021): 10152–10163.

[216] Y. Wang, T. Liu, G. Jiao, et al., “Exosomes From Adipose-Derived Mesenchymal Stem Cells Can Attenuate Liver Injury Caused by Minimally Invasive Hemihepatectomy Combined With Ischemia-Reperfusion in Minipigs by Modulating the Endoplasmic Reticulum Stress Response,” Life Sciences 321 (2023): 121618.

[217] Q. Zhang, C. Piao, J. Xu, et al., “ADSCs-Exo Attenuates Hepatic Ischemia-Reperfusion Injury After Hepatectomy by Inhibiting Endoplasmic Reticulum Stress and Inflammation,” Journal of Cellular Physiology 238, no. 3 (2023): 659–669.

[218] Y. Qu, Q. Zhang, X. Cai, et al., “Exosomes Derived From miR-181-5p-Modified Adipose-Derived Mesenchymal Stem Cells Prevent Liver Fibrosis via Autophagy Activation,” Journal of Cellular and Molecular Medicine 21, no. 10 (2017): 2491–2502.

[219] S. Baldari, G. Di Rocco, A. Magenta, et al., “Extracellular Vesicles-Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation,” Cells 8, no. 12 (2019): 1560.

[220] Y. Zhang, Y. Li, Q. Wang, et al., “Attenuation of Hepatic Ischemia-Reperfusion Injury by Adipose Stem Cell-Derived Exosome Treatment via ERK1/2 and GSK-3β Signaling Pathways,” International Journal of Molecular Medicine 49, no. 2 (2022): 13.

[221] G. Lou, L. Chen, C. Xia, et al., “MiR-199a-Modified Exosomes From Adipose Tissue-Derived Mesenchymal Stem Cells Improve Hepatocellular Carcinoma Chemosensitivity Through mTOR Pathway,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 4.

[222] G. Lou, X. Song, F. Yang, et al., “Exosomes Derived From miR-122-Modified Adipose Tissue-Derived MSCs Increase Chemosensitivity of Hepatocellular Carcinoma,” Journal of Hematology & Oncology 8 (2015): 122.

[223] A. Khosrojerdi, S. Soudi, A. Z. Hosseini, et al., “The Combination of Mesenchymal Stem Cell- and Hepatocyte-Derived Exosomes, Along With Imipenem, Ameliorates Inflammatory Responses and Liver Damage in a Sepsis Mouse Model,” Life Sciences 326 (2023): 121813.

[224] H. Imamura, Y. Tomimaru, S. Kobayashi, et al., “Adipose-Derived Stem Cells Using Fibrin Gel as a Scaffold Enhances Post-Hepatectomy Liver Regeneration,” Scientific Reports 15, no. 1 (2025): 6334.

[225] S. F. Ko, H. K. Yip, Y. Y. Zhen, et al., “Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features,” Stem Cells International 2015 (2015): 853506.

[226] M. Cao, Y. Zhao, T. Chen, et al., “Adipose Mesenchymal Stem Cell-Derived Exosomal microRNAs Ameliorate Polycystic Ovary Syndrome by Protecting Against Metabolic Disturbances,” Biomaterials 288 (2022): 121739.

[227] Q. Niu, T. Wang, Z. Wang, et al., “Adipose-Derived Mesenchymal Stem Cell-Secreted Extracellular Vesicles Alleviate Non-Alcoholic Fatty Liver Disease via Delivering miR-223-3p,” Adipocyte 11, no. 1 (2022): 572–587.

[228] Z. Zhang, J. Shang, Q. Yang, et al., “Exosomes Derived From Human Adipose Mesenchymal Stem Cells Ameliorate Hepatic Fibrosis by Inhibiting PI3K/Akt/mTOR Pathway and Remodeling Choline Metabolism,” Journal of Nanobiotechnology 21, no. 1 (2023): 29.

[229] H. Tilg, T. E. Adolph, and M. Trauner, “Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications,” Cell Metabolism 34, no. 11 (2022): 1700–1718.

[230] J. Sun, J. Zhang, X. Wang, et al., “Gut-Liver Crosstalk in Sepsis-Induced Liver Injury,” Critical Care 24, no. 1 (2020): 614.

[231] S. Anand and S. S. Mande, “Host-Microbiome Interactions: Gut-Liver Axis and Its Connection With Other Organs,” NPJ Biofilms and Microbiomes 8, no. 1 (2022): 89.

[232] A. Albillos, A. de Gottardi, and M. Rescigno, “The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy,” Journal of Hepatology 72, no. 3 (2020): 558–577.

[233] J. Aron-Wisnewsky, M. V. Warmbrunn, M. Nieuwdorp, et al., “Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?,” Gastroenterology 158, no. 7 (2020): 1881–1898.

[234] Y. Yin, A. Sichler, J. Ecker, et al., “Gut Microbiota Promote Liver Regeneration Through Hepatic Membrane Phospholipid Biosynthesis,” Journal of Hepatology 78, no. 4 (2023): 820–835.

[235] Y. Wang, Y. Zhou, Q. Wu, et al., “Honeysuckle-Derived Nanovesicles Regulate Gut Microbiota for the Treatment of Inflammatory Bowel Disease,” Advanced Science 12, no. 45 (2025): e05208.

[236] P. Li, Q. Wu, Y. Zhou, et al., “Honeysuckle-Derived Exosome-Like Nanovesicles Ameliorate Metabolic-Associated Fatty Liver Disease by Modulating Gut Microbiota and Its Metabolites,” Nano Research 18, no. 12 (2025): 94907986.

[237] H. Saeed, L. A. Díaz, A. Gil-Gómez, et al., “Microbiome-Centered Therapies for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease,” Clinical and Molecular Hepatology 31 (2025): S94–S111, Suppl.

[238] J. Mouries, P. Brescia, A. Silvestri, et al., “Microbiota-Driven Gut Vascular Barrier Disruption Is a Prerequisite for Non-Alcoholic Steatohepatitis Development,” Journal of Hepatology 71, no. 6 (2019): 1216–1228.

[239] S. Pezzino, M. Sofia, G. Faletra, et al., “Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome,” Biology 11, no. 11 (2022): 1622.

[240] D. Ferro, F. Baratta, D. Pastori, et al., “New Insights Into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress,” Nutrients 12, no. 9 (2020): 2762.

[241] A. Bruneau, J. Hundertmark, A. Guillot, et al., “Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases,” Frontiers in Medicine 8 (2021): 725390.

[242] I. Milosevic, A. Vujovic, A. Barac, et al., “Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature,” International Journal of Molecular Sciences 20, no. 2 (2019): 395.

[243] W. Jiang, N. Wu, X. Wang, et al., “Dysbiosis Gut Microbiota Associated With Inflammation and Impaired Mucosal Immune Function in Intestine of Humans With Non-Alcoholic Fatty Liver Disease,” Scientific Reports 5 (2015): 8096.

[244] D. Porras, E. Nistal, S. Martínez-Flórez, et al., “Protective Effect of Quercetin on High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice Is Mediated by Modulating Intestinal Microbiota Imbalance and Related Gut-Liver Axis Activation,” Free Radical Biology and Medicine 102 (2017): 188–202.

[245] Y. Rao, Z. Kuang, C. Li, et al., “Gut Akkermansia Muciniphila Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease by Regulating the Metabolism of L-Aspartate via Gut-Liver Axis,” Gut Microbes 13, no. 1 (2021): 1–19.

[246] E. J. Kang, M. G. Cha, G. H. Kwon, et al., “Akkermansia Muciniphila Improve Cognitive Dysfunction by Regulating BDNF and Serotonin Pathway in Gut-Liver-Brain Axis,” Microbiome 12, no. 1 (2024): 181.

[247] Z. Wang, S. Zhou, and Y. Jiang, “Sea Buckthorn Pulp and Seed Oils Ameliorate Lipid Metabolism Disorders and Modulate Gut Microbiota in C57BL/6J Mice on High-Fat Diet,” Frontiers in Nutrition 9 (2022): 1067813.

[248] G. Szabo and J. Petrasek, “Gut-Liver Axis and Sterile Signals in the Development of Alcoholic Liver Disease,” Alcohol and Alcoholism 52, no. 4 (2017): 414–424.

[249] X. Zhang, H. C. Lau, S. Ha, et al., “Intestinal TM6SF2 Protects Against Metabolic Dysfunction-Associated Steatohepatitis Through the Gut-Liver Axis,” Nature Metabolism 7, no. 1 (2025): 102–119.

[250] K. Yin, D. Wang, Y. Zhang, et al., “Dose-Effect of Polystyrene Microplastics on Digestive Toxicity in Chickens (Gallus Gallus): Multi-Omics Reveals Critical Role of Gut-Liver Axis,” Journal of Advanced Research 52 (2023): 3–18.

[251] L. Miele, V. Valenza, G. La Torre, et al., “Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease,” Hepatology 49, no. 6 (2009): 1877–1887.

[252] A. Gudan, K. Kozłowska-Petriczko, E. Wunsch, et al., “Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?,” Nutrients 15, no. 6 (2023): 1323.

[253] J. Yuan, C. Chen, J. Cui, et al., “Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella Pneumoniae,” Cell Metabolism 30, no. 4 (2019): 675–688.e677.

[254] T. Le Roy, M. Llopis, P. Lepage, et al., “Intestinal Microbiota Determines Development of Non-Alcoholic Fatty Liver Disease in Mice,” Gut 62, no. 12 (2013): 1787–1794.

[255] T. K. Soderborg, S. E. Clark, C. E. Mulligan, et al., “The Gut Microbiota in Infants of Obese Mothers Increases Inflammation and Susceptibility to NAFLD,” Nature Communications 9, no. 1 (2018): 4462.

[256] H. Xu, F. Fang, K. Wu, et al., “Gut Microbiota-Bile Acid Crosstalk Regulates Murine Lipid Metabolism via the Intestinal FXR-FGF19 Axis in Diet-Induced Humanized Dyslipidemia,” Microbiome 11, no. 1 (2023): 262.

[257] H. Zhang, C. Li, L. Han, et al., “MUP1 Mediates Urolithin A Alleviation of Chronic Alcohol-Related Liver Disease via Gut-Microbiota-Liver Axis,” Gut Microbes 16, no. 1 (2024): 2367342.

[258] H. Fang, F. F. Anhê, D. K. Zada, et al., “Gut Substrate Trap of D-Lactate From Microbiota Improves Blood Glucose and Fatty Liver Disease in Obese Mice,” Cell Metabolism 37, no. 9 (2025): 1806–1819.e1807.

[259] J. Boursier, O. Mueller, M. Barret, et al., “The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota,” Hepatology 63, no. 3 (2016): 764–775.

[260] Y. Zhang, D. Xu, X. Cai, et al., “Gut Commensal Barnesiella Intestinihominis Ameliorates Hyperglycemia and Liver Metabolic Disorders,” Advanced Science 12, no. 8 (2025): e2411181.

[261] L. Zhang, Z. Zheng, H. Huang, et al., “Multi-Omics Reveals Deoxycholic Acid Modulates Bile Acid Metabolism via the Gut Microbiota to Antagonize Carbon Tetrachloride-Induced Chronic Liver Injury,” Gut Microbes 16, no. 1 (2024): 2323236.

[262] S. Ha, V. W. Wong, X. Zhang, et al., “Interplay Between Gut Microbiome, Host Genetic and Epigenetic Modifications in MASLD and MASLD-Related Hepatocellular Carcinoma,” Gut 74, no. 1 (2024): 141–152.

[263] G. Lee, H. J. You, J. S. Bajaj, et al., “Distinct Signatures of Gut Microbiome and Metabolites Associated With Significant Fibrosis in Non-Obese NAFLD,” Nature Communications 11, no. 1 (2020): 4982.

[264] J. B. Schwimmer, J. S. Johnson, J. E. Angeles, et al., “Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease,” Gastroenterology 157, no. 4 (2019): 1109–1122.

[265] Q. Zhai, H. Wu, S. Zheng, et al., “Association Between Gut Microbiota and NAFLD/NASH: A Bidirectional Two-Sample Mendelian Randomization Study,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1294826.

[266] T. Bansal, R. C. Alaniz, T. K. Wood, et al., “The Bacterial Signal Indole Increases Epithelial-Cell Tight-Junction Resistance and Attenuates Indicators of Inflammation,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 1 (2010): 228–233.

[267] G. Kakiyama, W. M. Pandak, P. M. Gillevet, et al., “Modulation of the Fecal Bile Acid Profile by Gut Microbiota in Cirrhosis,” Journal of Hepatology 58, no. 5 (2013): 949–955.

[268] Y. Zhang, W. Liu, C. C. Wong, et al., “Catenibacteriummitsuokai Promotes Hepatocellular Carcinogenesis by Binding to Hepatocytes and Generating Quinolinic Acid,” Cell Metabolism 37, no. 10 (2025): 1998–2013.e7.

[269] H. C. Lau, X. Zhang, F. Ji, et al., “Lactobacillus Acidophilus Suppresses Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma Through Producing Valeric Acid,” EBioMedicine 100 (2024): 104952.

[270] E. J. Park, Y. S. Lee, S. M. Kim, et al., “Beneficial Effects of Lactobacillus Plantarum Strains on Non-Alcoholic Fatty Liver Disease in High Fat/High Fructose Diet-Fed Rats,” Nutrients 12, no. 2 (2020): 542.

[271] L. Zhu, R. Liao, J. Huang, et al., “Lactobacillus Salivarius SNK-6 Regulates Liver Lipid Metabolism Partly via the miR-130a-5p/MBOAT2 Pathway in a NAFLD Model of Laying Hens,” Cells 11, no. 24 (2022): 4133.

[272] Z. Farhat, N. D. Freedman, J. N. Sampson, et al., “A Prospective Investigation of Serum Bile Acids With Risk of Liver Cancer, Fatal Liver Disease, and Biliary Tract Cancer,” Hepatology Communications 6, no. 9 (2022): 2391–2399.

[273] Q. Chen, L. Zhao, L. Mei, et al., “Vitamin C and Vitamin D(3) Alleviate Metabolic-Associated Fatty Liver Disease by Regulating the Gut Microbiota and Bile Acid Metabolism via the Gut-Liver Axis,” Frontiers in Pharmacology 14 (2023): 1163694.

[274] E. Somm and F. R. Jornayvaz, “Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives,” Endocrine Reviews 39, no. 6 (2018): 960–989.

[275] A. Dalla Via, G. Gargari, V. Taverniti, et al., “Urinary TMAO Levels Are Associated With the Taxonomic Composition of the Gut Microbiota and With the Choline TMA-Lyase Gene (cutC) Harbored by Enterobacteriaceae,” Nutrients 12, no. 1 (2019): 62.

[276] C. Caussy, C. Hsu, M. T. Lo, et al., “Link Between Gut-Microbiome Derived Metabolite and Shared Gene-Effects With Hepatic Steatosis and Fibrosis in NAFLD,” Hepatology 68, no. 3 (2018): 918–932.

[277] P. Chen, M. Torralba, J. Tan, et al., “Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-Induced Liver Injury in Mice,” Gastroenterology 148, no. 1 (2015): 203–214.e216.

[278] A. Villard, J. Boursier, and R. Andriantsitohaina, “Bacterial and Eukaryotic Extracellular Vesicles and Nonalcoholic Fatty Liver Disease: New Players in the Gut-Liver Axis?,” American Journal of Physiology-Gastrointestinal and Liver Physiology 320, no. 4 (2021): G485–G495.

[279] C. Li, J. Yao, C. Yang, et al., “Gut Microbiota-Derived Short Chain Fatty Acids Act as Mediators of the Gut-Liver-Brain Axis,” Metabolic Brain Disease 40, no. 2 (2025): 122.

[280] D. Zhang, Y. P. Jian, Y. N. Zhang, et al., “Short-Chain Fatty Acids in Diseases,” Cell Communication and Signaling 21, no. 1 (2023): 212.

[281] C. Hu, B. Xu, X. Wang, et al., “Gut Microbiota-Derived Short-Chain Fatty Acids Regulate Group 3 Innate Lymphoid Cells in HCC,” Hepatology 77, no. 1 (2023): 48–64.

[282] S. Zhao, C. Jang, J. Liu, et al., “Dietary Fructose Feeds Hepatic Lipogenesis via Microbiota-Derived Acetate,” Nature 579, no. 7800 (2020): 586–591.

[283] J. Xu, H. Tian, Y. Ji, et al., “Urolithin C Reveals Anti-NAFLD Potential via AMPK-Ferroptosis Axis and Modulating Gut Microbiota,” Naunyn-Schmiedeberg's Archives of Pharmacology 396, no. 10 (2023): 2687–2699.

[284] R. Martín-Mateos and A. Albillos, “The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease,” Frontiers in Immunology 12 (2021): 660179.

[285] Q. Jiao, J. Liu, L. Zhou, et al., “Lactobacillus Extracellular Vesicles Alleviate Alcohol-Induced Liver Injury in Mice by Regulating Gut Microbiota and Activating the Nrf-2 Signaling Pathway,” Food & Function 16, no. 4 (2025): 1284–1298.

[286] L. Fizanne, A. Villard, N. Benabbou, et al., “Faeces-Derived Extracellular Vesicles Participate in the Onset of Barrier Dysfunction Leading to Liver Diseases,” Journal of Extracellular Vesicles 12, no. 2 (2023): e12303.

[287] X. Yang, J. Wang, X. Qi, et al., “HLF and PPARα Axis Regulates Metabolic-Associated Fatty Liver Disease Through Extracellular Vesicles Derived From the Intestinal Microbiota,” iMeta 4, no. 2 (2025): e70022.

[288] L. Zhu, J. Huang, Z. Luo, et al., “Lactobacillus Salivarius Extracellular Vesicles Enhance Gut and Liver Function in MAFLD,” Frontiers in Immunology 16 (2025): 1660131.

[289] E. Behzadi, H. Mahmoodzadeh Hosseini, and A. A. Imani Fooladi, “The Inhibitory Impacts of Lactobacillus Rhamnosus GG-Derived Extracellular Vesicles on the Growth of Hepatic Cancer Cells,” Microbial Pathogenesis 110 (2017): 1–6.

[290] X. Liu, Y. Wang, A. A. Medina, et al., “Probiotic-Derived Extracellular Vesicles Attenuate Cholestatic Liver Damage via Gut-Liver Axis,” Pharmacological Research 225 (2026): 108152.

[291] S. Martínez-Ruiz, J. Badia, and L. Baldoma, “Extracellular Vesicles From Escherichia Coli Strains of the Gut Microbiota Trigger Hepatic Antioxidant and Anti-Lipogenic Effects via the Gut-Liver Axis in Healthy Neonatal Rats,” Nutrients 17, no. 19 (2025): 3066.

[292] H. Zhou, W. Huang, J. Li, et al., “Oral Probiotic Extracellular Vesicle Therapy Mitigates Influenza A Virus Infection via Blunting IL-17 Signaling,” Bioactive Materials 45 (2025): 401–416.

[293] A. J. Ruiz-Malagón, M. Herraiz-Vilela, J. Pinazo-Bandera, et al., “An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury,” Journal of Extracellular Vesicles 15, no. 3 (2026): e70240.

[294] Z. Luo, Y. Ji, D. Zhang, et al., “Microbial DNA Enrichment Promotes Liver Steatosis and Fibrosis in the Course of Non-Alcoholic Steatohepatitis,” Acta Physiologica 235, no. 3 (2022): e13827.

[295] Y. Wang, X. Chen, B. Tian, et al., “Nucleolin-Targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer,” Theranostics 7, no. 5 (2017): 1360–1372.

[296] Y. Zhou, T. Du, C. L. Yang, et al., “Extracellular Vesicles Encapsulated With Caspase-1 Inhibitor Ameliorate Experimental Autoimmune Myasthenia Gravis Through Targeting Macrophages,” Journal of Controlled Release 364 (2023): 458–472.

[297] Y. Wan, L. Li, R. Chen, et al., “Engineered Extracellular Vesicles Efficiently Deliver CRISPR-Cas9 Ribonucleoprotein (RNP) to Inhibit Herpes Simplex Virus1 Infection in Vitro and in Vivo,” Acta Pharmaceutica Sinica B 14, no. 3 (2024): 1362–1379.

[298] I. K. Herrmann, M. J. A. Wood, and G. Fuhrmann, “Extracellular Vesicles as a Next-Generation Drug Delivery Platform,” Nature Nanotechnology 16, no. 7 (2021): 748–759.

[299] Z. L. Hu, Z. Q. Li, Y. Wang, et al., “Extracellular Vesicles Derived EBV Tegument Protein BRRF2 Suppresses cGAS Phase Separation to Promote Anti-Viral Innate Immune Evasion,” Nature Communications 16, no. 1 (2025): 9015.

[300] D. W. Greening, R. Xu, A. Rai, et al., “Clinical Relevance of Extracellular Vesicles in Cancer—therapeutic and Diagnostic Potential,” Nature Reviews Clinical Oncology 22, no. 12 (2025): 924–952.

[301] L. Yang, S. Wang, Z. Qiao, et al., “Dual-Ligand Engineered Exosome Regulates WNT Signaling Activation to Promote Liver Repair and Regeneration,” Nature Communications 16, no. 1 (2025): 9019.

[302] W. Du, C. Chen, Y. Liu, et al., “A Combined “Eat Me/Don't Eat Me” Strategy Based on Exosome for Acute Liver Injury Treatment,” Cell Reports Medicine 6, no. 4 (2025): 102033.

[303] L. Alvarez-Erviti, Y. Seow, H. Yin, et al., “Delivery of siRNA to the Mouse Brain by Systemic Injection of Targeted Exosomes,” Nature Biotechnology 29, no. 4 (2011): 341–345.

[304] W. Feng, Y. Teng, Q. Zhong, et al., “Biomimetic Grapefruit-Derived Extracellular Vesicles for Safe and Targeted Delivery of Sodium Thiosulfate Against Vascular Calcification,” ACS Nano 17, no. 24 (2023): 24773–24789.

[305] P. Shamshiripour, M. Rahnama, M. Nikoobakht, et al., “Extracellular Vesicles Derived From Dendritic Cells Loaded With VEGF-A siRNA and Doxorubicin Reduce Glioma Angiogenesis in Vitro,” Journal of Controlled Release 369 (2024): 128–145.

[306] X. Zhu, M. Badawi, S. Pomeroy, et al., “Comprehensive Toxicity and Immunogenicity Studies Reveal Minimal Effects in Mice Following Sustained Dosing of Extracellular Vesicles Derived From HEK293T Cells,” Journal of Extracellular Vesicles 6, no. 1 (2017): 1324730.

[307] E. D. Ianni, W. Obuchi, K. Breyne, et al., “Extracellular Vesicles for the Delivery of Gene Therapy,” Nature Reviews Bioengineering 3, no. 5 (2025): 360–373.

[308] J. Wang, X. Zhang, Y. Zhu, et al., “Adipocyte-Derived Extracellular Vesicles Are Key Regulators of Central Leptin Sensitivity and Energy Homeostasis,” Cell Metabolism 38, no. 1 (2025): 82–99, S1550-4131(25)00439-5.

[309] J. E. Kim, Y. E. Ji, H. J. Hwang, et al., “Engineered MSC-EVs Loaded With BDNF-Enhancing Neuropeptides via a Non-Disruptive Method Enhance Post-Stroke Neuroregeneration via Intranasal Delivery,” Journal of Nanobiotechnology 23, no. 1 (2025): 594.

[310] T. T. Lu, J. Zhang, J. Cai, et al., “Extracellular Vesicles Derived From Mesenchymal Stromal Cells as Nanotherapeutics for Liver Ischaemia-Reperfusion Injury by Transferring Mitochondria to Modulate the Formation of Neutrophil Extracellular Traps,” Biomaterials 284 (2022): 121486.

[311] J. Zhang, X. Qiu, Y. Lei, et al., “Engineered EVs From LncEEF1G—overexpressing MSCs Promote Fibrotic Liver Regeneration by Upregulating HGF Release From Hepatic Stellate Cells,” Experimental And Molecular Medicine 57, no. 3 (2025): 584–600.

[312] J. Fang and W. Liang, “ASCs -Derived Exosomes Loaded With Vitamin A and Quercetin Inhibit Rapid Senescence-Like Response After Acute Liver Injury,” Biochemical and Biophysical Research Communications 572 (2021): 125–130.

[313] C. Yang, Z. Guan, X. Pang, et al., “Desialylated Mesenchymal Stem Cells-Derived Extracellular Vesicles Loaded With Doxorubicin for Targeted Inhibition of Hepatocellular Carcinoma,” Cells 11, no. 17 (2022): 2642.

[314] Y. Jin, R. Shi, T. Qi, et al., “Adipose-Derived Stem Cells Show Hepatic Differentiation Potential and Therapeutic Effect in Rats With Acute Liver Failure,” Acta Biochimica et Biophysica Sinica 55, no. 4 (2023): 601–612.

[315] J. Xiao, X. Gong, Z. Fu, et al., “The Influence of Inflammation on the Characteristics of Adipose-Derived Mesenchymal Stem Cells (ADMSCs) and Tissue Repair Capability in a Hepatic Injury Mouse Model,” Stem Cell Research & Therapy 14, no. 1 (2023): 334.

[316] O. H. Kim, H. E. Hong, H. Seo, et al., “Generation of Induced Secretome From Adipose-Derived Stem Cells Specialized for Disease-Specific Treatment: An Experimental Mouse Model,” World Journal of Stem Cells 12, no. 1 (2020): 70–86.

[317] T. Lener, M. Gimona, L. Aigner, et al., “Applying Extracellular Vesicles Based Therapeutics in Clinical Trials—an ISEV Position Paper,” Journal of Extracellular Vesicles 4 (2015): 30087.

[318] A. Garling, F. Auvray, M. Epardaud, et al., “Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges,” Journal of Extracellular Vesicles 14, no. 9 (2025): e70150.

[319] M. Zhao, M. He, X. Lin, et al., “Identification of Outer Membrane Vesicles as a New Vehicle Mediating Antibiotic Resistance Gene Transfer in Campylobacter,” Journal of Extracellular Vesicles 14, no. 11 (2025): e70195.

[320] A. P. Domínguez Rubio, C. L. D'Antoni, M. Piuri, et al., “Probiotics, Their Extracellular Vesicles and Infectious Diseases,” Frontiers in Microbiology 13 (2022): 864720.

[321] A. Razim, A. Zabłocka, A. Schmid, et al., “Bacterial Extracellular Vesicles as Intranasal Postbiotics: Detailed Characterization and Interaction With Airway Cells,” Journal of Extracellular Vesicles 13, no. 10 (2024): e70004.

[322] R. Nakao, H. Kobayashi, Y. Iwabuchi, et al., “A Highly Immunogenic Vaccine Platform Against Encapsulated Pathogens Using Chimeric Probiotic Escherichia Coli Membrane Vesicles,” NPJ Vaccines 7, no. 1 (2022): 153.

[323] M. Bittel, P. Reichert, I. Sarfati, et al., “Visualizing Transfer of Microbial Biomolecules by Outer Membrane Vesicles in Microbe-Host-Communication in Vivo,” Journal of Extracellular Vesicles 10, no. 12 (2021): e12159.

[324] Q. Chen, Z. Fang, Z. Yang, et al., “Lactobacillus Plantarum-Derived Extracellular Vesicles Modulate Macrophage Polarization and Gut Homeostasis for Alleviating Ulcerative Colitis,” Journal of Agricultural and Food Chemistry 72, no. 26 (2024): 14713–14726.

[325] W. Kim, E. J. Lee, I. H. Bae, et al., “Lactobacillus Plantarum-Derived Extracellular Vesicles Induce Anti-Inflammatory M2 Macrophage Polarization in Vitro,” Journal of Extracellular Vesicles 9, no. 1 (2020): 1793514.

[326] J. Wang, X. Li, X. Zhao, et al., “Lactobacillus Rhamnosus GG-Derived Extracellular Vesicles Promote Wound Healing via miR-21-5p-Mediated Re-Epithelization and Angiogenesis,” Journal of Nanobiotechnology 22, no. 1 (2024): 644.

[327] M. Morishita, M. Kida, T. Motomura, et al., “Elucidation of the Tissue Distribution and Host Immunostimulatory Activity of Exogenously Administered Probiotic-Derived Extracellular Vesicles for Immunoadjuvant,” Molecular Pharmaceutics 20, no. 12 (2023): 6104–6113.

[328] J. Deng, Y. Hu, P. Zhu, et al., “Probiotic Delivery for Editing of the Gut Microbiota to Mitigate Colitis and Maintain Hepatic Homeostasis via Gut-Liver Axis,” ACS Nano 19, no. 10 (2025): 10500–10514.

[329] C. Wu, S. Xiang, H. Wang, et al., “Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease,” ACS Applied Materials & Interfaces 16, no. 8 (2024): 9854–9867.

[330] X. Huang, S. Zhang, and Z. Wang, “Therapeutic Potential of Extracellular Vesicles in Inflammatory Diseases,” Extracellular Vesicle 5 (2025): 100058.

[331] Y. Wang, M. Hu, M. Spanos, et al., “Bioengineering Extracellular Vesicles for Enhanced Therapeutic Functionality and Clinical Potential in the Cardiovascular System,” Science Bulletin 71, no. 6 (2026): 1524–1545.

[332] O. P. B. Wiklander, M. Brennan, J. Lötvall, et al., “Advances in Therapeutic Applications of Extracellular Vesicles,” Science Translational Medicine 11, no. 492 (2019): eaav8521.

[333] Q. Niu, T. Wang, J. Li, et al., “Molecular Therapy for Non-Alcoholic Fatty Liver Disease: Angiotensin-(1-7) Delivery via Cyclic RGD-Modified Vesicles Activates Mas Receptor to Ameliorate Fibrosis Through Autophagy and Metabolic Reprogramming,” Faseb Journal 40, no. 2 (2026): e71360.

[334] Y. T. Lu, T. Y. Chen, H. H. Lin, et al., “Small Extracellular Vesicles Engineered Using Click Chemistry to Express Chimeric Antigen Receptors Show Enhanced Efficacy in Acute Liver Failure,” Journal of Extracellular Vesicles 14, no. 2 (2025): e70044.

[335] K. Strohmeier, M. Hofmann, F. Hauser, et al., “CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis,” International Journal of Molecular Sciences 23, no. 1 (2021): 282.

[336] Y. Pan, X. Yang, Z. Zeng, et al., “(124)I-Labelled BMSC-Derived Extracellular Vesicles Deliver CRISPR/Cas9 Ribonucleoproteins With a GFP-Reporter System to Inhibit Osteosarcoma Proliferation and Metastasis,” Journal of Extracellular Vesicles 14, no. 7 (2025): e70130.

[337] A. Ivanova, L. Badertscher, G. O'Driscoll, et al., “Creating Designer Engineered Extracellular Vesicles for Diverse Ligand Display, Target Recognition, and Controlled Protein Loading and Delivery,” Advanced Science 10, no. 34 (2023): e2304389.

[338] F. Yu, Z. Liu, J. Feng, et al., “Hyaluronic Acid Modified Extracellular Vesicles Targeting Hepatic Stellate Cells to Attenuate Hepatic Fibrosis,” European Journal of Pharmaceutical Sciences 198 (2024): 106783.

[339] S. Zhu, W. Xu, Z. Chen, et al., “Nuciferine Exerts Anti-Inflammatory Effects in Mice With Non-Alcoholic Steatohepatitis by Regulating the miR-23a-3p-SIRT1-NF-κB Pathway and Akkermansia Muciniphila -Extracellular Vesicles,” Phytotherapy Research 39, no. 8 (2025): 3508–3525.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.